Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival.

作者信息

Gomes Rodrigo Vieira, Rodrigues Michele Ângela, Rodrigues João Bernardo Sancio Rocha, Vidigal Paula Teixeira, Damasceno Karine Araújo, Lima Henrique Araújo, Gomes Dawidson Assis, Machado Carla Jorge, Resende Vivian

机构信息

- Faculty of Medicine, Surgery Department, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

- Institute of Biological Sciences, General Pathology, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.

出版信息

Rev Col Bras Cir. 2018 Jul 10;45(3):e1826. doi: 10.1590/0100-6991e-20181826.

DOI:10.1590/0100-6991e-20181826

PMID:29995151

Abstract

OBJECTIVE

to evaluate the expression of the epithelial growth factor receptor (EGFR) by immunohistochemistry, and to verify its association with prognostic factors and survival of patients operated by cholangiocarcinoma.

METHODS

we verified the immunohistochemical expression of EGFR in 35 surgical specimens of cholangiocarcinoma (CCA). We obtained survival curves with the Kaplan-Meier method.

RESULTS

we found significant EGFR expression in ten (28.6%) of the 35 CCAs, eight with score 3 and two with score 2. Advanced stages (III and IV) presented higher EGFR expression (p=0.07). The clinical characteristics that were most associated with positive EGFR expression were female gender (p=0.06) and absence of comorbidities (p=0.06). Overall survival at 12, 24, 36 and 48 months was 100%, 82.5%, 59% and 44.2%, respectively. The survival of EGFR positive patients at 12, 24, 36 and 48 months was 100%, 75%, 50% and 0%, whereas for negative EGFR patients it was 100%, 87.5%, 65.6% and 65.6%, respectively.